Cantor Fitzgerald Reiterates $13.00 Price Target for Axsome Therapeutics, Inc. (AXSM)
Separately, Zacks Investment Research raised shares of Axsome Therapeutics from a sell rating to a hold rating in a research note on Wednesday, October 19th.
Axsome Therapeutics (NASDAQ:AXSM) opened at 4.30 on Tuesday. The company’s market capitalization is $82.36 million. The stock’s 50 day moving average is $5.20 and its 200 day moving average is $6.72. Axsome Therapeutics has a 52 week low of $4.25 and a 52 week high of $12.69.
This piece was published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The legal version of this piece can be accessed at http://www.dailypolitical.com/2017/02/17/cantor-fitzgerald-reiterates-13-00-price-target-for-axsome-therapeutics-inc-axsm.html.
Institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. boosted its position in Axsome Therapeutics by 0.7% in the third quarter. JPMorgan Chase & Co. now owns 1,592,856 shares of the company’s stock valued at $12,552,000 after buying an additional 10,625 shares during the last quarter. Lombard Odier Asset Management USA Corp boosted its position in Axsome Therapeutics by 2.8% in the second quarter. Lombard Odier Asset Management USA Corp now owns 341,790 shares of the company’s stock valued at $2,577,000 after buying an additional 9,400 shares during the last quarter. California State Teachers Retirement System bought a new position in Axsome Therapeutics during the second quarter valued at $176,000. Schwab Charles Investment Management Inc. bought a new position in Axsome Therapeutics during the second quarter valued at $134,000. Finally, State Street Corp boosted its position in Axsome Therapeutics by 6.7% in the fourth quarter. State Street Corp now owns 134,688 shares of the company’s stock valued at $908,000 after buying an additional 8,466 shares during the last quarter. 33.07% of the stock is owned by institutional investors.
About Axsome Therapeutics
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.
Receive News & Ratings for Axsome Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.